188:@0.017061:0.038809:0.056572:0.038809:0.056572:0.019212:0.017061:0.019212:0.013170:0.013170:0.013170
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
Panitumumab  :@0.084848:0.077985:0.241353:0.077985:0.241353:0.059964:0.084848:0.059964:0.011973:0.014111:0.012828:0.005131:0.006414:0.012828:0.020098:0.012828:0.020098:0.014111:0.014111:0.005987:0.005987
Panitumumab  is a recombinant,  human :@0.084848:0.096300:0.480792:0.096300:0.480792:0.080544:0.084848:0.080544:0.011392:0.013143:0.011738:0.003848:0.006523:0.011699:0.018049:0.011699:0.018049:0.013143:0.013123:0.005330:0.004820:0.003848:0.007466:0.010160:0.013143:0.010160:0.005713:0.012508:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.011738:0.006523:0.005330:0.005330:0.004814:0.011738:0.011699:0.018049:0.013143:0.011738:0.005330
IgG2 kappa monoclonal antibody that :@0.084848:0.112003:0.480780:0.112003:0.480780:0.096247:0.084848:0.096247:0.004349:0.012950:0.016779:0.010660:0.012161:0.009660:0.013143:0.013123:0.013123:0.013143:0.012161:0.018049:0.012604:0.011738:0.012604:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.012161:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.010314:0.012161:0.006523:0.011738:0.013143:0.006523:0.005330
binds  specifically  to  the  human  EGFR.  :@0.084848:0.127706:0.480784:0.127696:0.480784:0.111940:0.084848:0.111950:0.013123:0.003848:0.011738:0.013181:0.007466:0.005330:0.004784:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330:0.004791:0.006523:0.012604:0.005330:0.004768:0.006523:0.011738:0.012508:0.005330:0.004768:0.011738:0.011699:0.018049:0.013143:0.011738:0.005330:0.004770:0.010314:0.016779:0.009333:0.011680:0.005330:0.018648:0.816268
121:@0.456803:0.122077:0.475447:0.122077:0.475447:0.112892:0.456803:0.112892:0.006215:0.006215:0.006215
The  EGFR  is a transmembrane  glycopro-:@0.084852:0.143399:0.475471:0.143399:0.475471:0.127643:0.084852:0.127643:0.008197:0.011738:0.012508:0.005330:0.003870:0.010314:0.016779:0.009333:0.011680:0.005330:0.003875:0.003848:0.007466:0.009217:0.013143:0.009217:0.006523:0.005792:0.013143:0.011738:0.007466:0.018049:0.012508:0.018049:0.013123:0.005792:0.013143:0.011738:0.012508:0.005330:0.003877:0.012950:0.003848:0.010314:0.012450:0.012604:0.013123:0.005713:0.012604:0.006388
tein that is a member of a subfamily  of :@0.084852:0.159102:0.480782:0.159102:0.480782:0.143346:0.084852:0.143346:0.006523:0.012508:0.003848:0.011738:0.009448:0.006523:0.011738:0.013143:0.006523:0.009448:0.003848:0.007466:0.009448:0.013143:0.009448:0.018049:0.012508:0.018049:0.013123:0.012508:0.005792:0.009448:0.012604:0.006042:0.009448:0.013143:0.009448:0.007466:0.011699:0.013123:0.006042:0.013143:0.018049:0.003848:0.003848:0.010314:0.005330:0.004135:0.012604:0.006042:0.005330
type I receptor tyrosine kinases, including :@0.084852:0.174805:0.480786:0.174805:0.480786:0.159049:0.084852:0.159049:0.006523:0.010314:0.013123:0.012508:0.007081:0.004349:0.007081:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.007068:0.006523:0.010314:0.005713:0.012604:0.007466:0.003848:0.011738:0.012508:0.007081:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.007466:0.005330:0.007081:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.005330
EGFR, HER2, HER3, and HER4. EGFR is con-:@0.084852:0.190508:0.475435:0.190508:0.475435:0.174752:0.084852:0.174752:0.010314:0.016779:0.009333:0.011680:0.005330:0.006158:0.013143:0.010314:0.011680:0.010660:0.005330:0.006158:0.013143:0.010314:0.011680:0.010660:0.005330:0.006158:0.013143:0.011738:0.013181:0.006158:0.013143:0.010314:0.011680:0.010660:0.005330:0.006158:0.010314:0.016779:0.009333:0.011680:0.006158:0.003848:0.007466:0.006158:0.012450:0.012604:0.011738:0.006388
stitutively expressed in normal epithelial tis-:@0.084852:0.206211:0.475466:0.206211:0.475466:0.190455:0.084852:0.190455:0.007466:0.006523:0.003848:0.006523:0.011699:0.006523:0.003848:0.010660:0.012508:0.003848:0.010314:0.004541:0.012508:0.009236:0.013123:0.005713:0.012508:0.007466:0.007466:0.012508:0.013181:0.004541:0.003848:0.011738:0.004532:0.011738:0.012604:0.006315:0.018049:0.013143:0.003848:0.004541:0.012508:0.013123:0.003848:0.006523:0.011738:0.012508:0.003848:0.003848:0.013143:0.003848:0.004541:0.006523:0.003848:0.007466:0.006388
sues, including the  skin and hair follicle :@0.084852:0.221914:0.480809:0.221914:0.480809:0.206158:0.084852:0.206158:0.007466:0.011699:0.012508:0.007466:0.005330:0.010968:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.010968:0.006523:0.011738:0.012508:0.005330:0.005625:0.007466:0.009660:0.003848:0.011738:0.010968:0.013143:0.011738:0.013181:0.010968:0.011738:0.013143:0.003848:0.005792:0.010968:0.006042:0.012604:0.003848:0.003848:0.003848:0.012450:0.003848:0.012508:0.005330
and over-expressed in certain  human :@0.084852:0.237617:0.480801:0.237617:0.480801:0.221861:0.084852:0.221861:0.013143:0.011738:0.013181:0.015740:0.012604:0.010660:0.012508:0.005792:0.006388:0.012508:0.009236:0.013123:0.005705:0.012508:0.007466:0.007466:0.012508:0.013181:0.015740:0.003848:0.011738:0.015740:0.012450:0.012508:0.005792:0.006523:0.013143:0.003848:0.011738:0.005330:0.010399:0.011738:0.011699:0.018049:0.013143:0.011738:0.005330
cancers, including colon and rectal can-:@0.084852:0.253320:0.475452:0.253320:0.475452:0.237564:0.084852:0.237564:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.005330:0.007043:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.007043:0.012450:0.012604:0.003848:0.012604:0.011738:0.007043:0.013143:0.011738:0.013181:0.007043:0.005713:0.012508:0.012450:0.006523:0.013143:0.003848:0.007043:0.012450:0.013143:0.011738:0.006388
cers. Binding of ligands to EGFR ultimately :@0.084852:0.269023:0.480784:0.269023:0.480784:0.253267:0.084852:0.253267:0.012450:0.012508:0.005792:0.007466:0.005330:0.006052:0.011045:0.003848:0.011738:0.013181:0.003848:0.011738:0.012950:0.006061:0.012604:0.006042:0.006061:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.007466:0.006061:0.006523:0.012604:0.006052:0.010314:0.016779:0.009333:0.011680:0.006061:0.011699:0.003848:0.006523:0.003848:0.018049:0.013143:0.006523:0.012508:0.003848:0.010314:0.005330
results  in  transcription  of  genes  involved :@0.084852:0.284726:0.480788:0.284726:0.480788:0.268970:0.084852:0.268970:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.005330:0.004743:0.003848:0.011738:0.005330:0.004737:0.006523:0.005792:0.013143:0.011738:0.007466:0.012450:0.005792:0.003848:0.013123:0.006523:0.003848:0.012604:0.011738:0.005330:0.004736:0.012604:0.006042:0.005330:0.004736:0.012950:0.012508:0.011738:0.012508:0.007466:0.005330:0.004741:0.003848:0.011738:0.010660:0.012604:0.003848:0.010660:0.012508:0.013181:0.005330
with cellular growth and survival, motility, :@0.084852:0.300429:0.480801:0.300429:0.480801:0.284673:0.084852:0.284673:0.015990:0.003848:0.006523:0.011738:0.007697:0.012450:0.012508:0.003848:0.003848:0.011699:0.003848:0.013143:0.005792:0.007697:0.012950:0.005709:0.012604:0.015990:0.006523:0.011738:0.007682:0.013143:0.011738:0.013181:0.007697:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.007697:0.018049:0.012604:0.006523:0.003848:0.003848:0.003848:0.006523:0.010314:0.005330:0.005330
and proliferation. :@0.084852:0.316132:0.250239:0.316132:0.250239:0.300376:0.084852:0.300376:0.013143:0.011738:0.013181:0.005330:0.013123:0.005713:0.012604:0.003848:0.003848:0.006042:0.012508:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.005330
Panitumumab binds specifically to EGFR :@0.103036:0.331835:0.480784:0.331835:0.480784:0.316079:0.103036:0.316079:0.011392:0.013143:0.011738:0.003848:0.006523:0.011699:0.018049:0.011699:0.018049:0.013143:0.013123:0.005259:0.013123:0.003848:0.011738:0.013181:0.007466:0.005269:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.013143:0.003848:0.003848:0.010314:0.005270:0.006523:0.012604:0.005253:0.010314:0.016779:0.009333:0.011680:0.005330
on  both  normal and tumour  cells, and :@0.084852:0.347538:0.480798:0.347538:0.480798:0.331782:0.084852:0.331782:0.012604:0.011738:0.005330:0.006106:0.013123:0.012604:0.006523:0.011738:0.005330:0.006106:0.011738:0.012604:0.006315:0.018049:0.013143:0.003848:0.011449:0.013143:0.011738:0.013181:0.011449:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005330:0.006098:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330:0.011449:0.013143:0.011738:0.013181:0.005330
competitively inhibits the  binding of li-:@0.084852:0.363241:0.475444:0.363241:0.475444:0.347486:0.084852:0.347486:0.012450:0.012604:0.018049:0.013123:0.012508:0.006523:0.003848:0.006523:0.003848:0.010660:0.012508:0.003848:0.010314:0.013547:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.007466:0.013547:0.006523:0.011738:0.012508:0.005330:0.008207:0.013123:0.003848:0.011738:0.013181:0.003848:0.011738:0.012950:0.013547:0.012604:0.006042:0.013547:0.003848:0.003848:0.006388
gands for EGFR. :@0.084852:0.378944:0.237195:0.378944:0.237195:0.363189:0.084852:0.363189:0.012950:0.013143:0.011738:0.013181:0.007466:0.005330:0.006042:0.012604:0.005792:0.005330:0.010314:0.016779:0.009333:0.011680:0.005330:0.005330
Panitumumab is indicated as a single :@0.084852:0.395084:0.437085:0.395084:0.437085:0.379328:0.084852:0.379328:0.011392:0.013143:0.011738:0.003848:0.006523:0.011699:0.018049:0.011699:0.018049:0.013143:0.013123:0.005330:0.003848:0.007466:0.005330:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.005330:0.013143:0.007466:0.005330:0.013143:0.005330:0.007466:0.003848:0.011738:0.012950:0.003848:0.012508:0.005330
agent for the treatment of metastatic :@0.084852:0.411224:0.440916:0.411224:0.440916:0.395468:0.084852:0.395468:0.013143:0.012950:0.012508:0.011738:0.006523:0.005330:0.006042:0.012604:0.005792:0.005330:0.006523:0.011738:0.012508:0.005330:0.006523:0.005678:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.012604:0.006042:0.005330:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330
colorectal carcinoma with disease pro-:@0.084852:0.427363:0.450987:0.427363:0.450987:0.411607:0.084852:0.411607:0.012450:0.012604:0.003848:0.012604:0.005707:0.012508:0.012450:0.006523:0.013143:0.003848:0.005330:0.012450:0.013143:0.005655:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.013123:0.005715:0.012604:0.006388
gression on or following fluoropyrimidine, :@0.084852:0.443503:0.465502:0.443503:0.465502:0.427747:0.084852:0.427747:0.012950:0.005709:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.012604:0.011738:0.005330:0.012604:0.005792:0.005330:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.004666:0.004666:0.011699:0.012604:0.005678:0.012604:0.013123:0.010314:0.005792:0.003848:0.018049:0.003848:0.013181:0.003848:0.011738:0.012508:0.005330:0.005330
oxaliplatin, and irinotecan chemotherapy :@0.084852:0.459642:0.479149:0.459642:0.479149:0.443886:0.084852:0.443886:0.012604:0.009236:0.013143:0.003848:0.003848:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.005330:0.005330:0.013143:0.011738:0.013181:0.005330:0.003848:0.005792:0.003848:0.011738:0.012604:0.006523:0.012508:0.012450:0.013143:0.011738:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
regimens.:@0.084852:0.475782:0.174963:0.475782:0.174963:0.460026:0.084852:0.460026:0.005713:0.012508:0.012950:0.003848:0.018049:0.012508:0.011738:0.007466:0.005330
121:@0.174953:0.470084:0.193598:0.470084:0.193598:0.460899:0.174953:0.460899:0.006215:0.006215:0.006215
PD-1 inhibitors:@0.084848:0.506541:0.230235:0.506541:0.230235:0.488520:0.084848:0.488520:0.011973:0.014966:0.008980:0.011973:0.005987:0.005131:0.012828:0.012828:0.005131:0.014111:0.005131:0.006414:0.013683:0.006842:0.009407
Pembrolizumab,  nivolumab, atezolizum-:@0.084848:0.524856:0.475469:0.524856:0.475469:0.509100:0.084848:0.509100:0.011392:0.012508:0.018049:0.013123:0.005709:0.012604:0.003848:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.005330:0.005330:0.010166:0.011738:0.003848:0.010660:0.012604:0.003848:0.011699:0.018049:0.013143:0.013123:0.005330:0.015509:0.013143:0.006523:0.012508:0.008178:0.012604:0.003848:0.003848:0.008178:0.011699:0.018049:0.006388
ab, avelumab and durvalumab all have a :@0.084848:0.540559:0.480780:0.540559:0.480780:0.524803:0.084848:0.524803:0.013143:0.013123:0.005330:0.004734:0.013143:0.010660:0.012508:0.003848:0.011699:0.018049:0.013143:0.013123:0.004734:0.013143:0.011738:0.013181:0.004734:0.013181:0.011699:0.005792:0.010660:0.013143:0.003848:0.011699:0.018049:0.013143:0.013123:0.004734:0.013143:0.003848:0.003848:0.004734:0.011738:0.013143:0.010660:0.012508:0.004734:0.013143:0.005330
similar mechanism of action. These agents :@0.084848:0.556262:0.480795:0.556262:0.480795:0.540506:0.084848:0.540506:0.007466:0.003848:0.018049:0.003848:0.003848:0.013143:0.005792:0.004926:0.018049:0.012508:0.012450:0.011738:0.013143:0.011738:0.003848:0.007466:0.018049:0.004926:0.012604:0.006042:0.004916:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.004913:0.008197:0.011738:0.012508:0.007466:0.012508:0.004926:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330
are humanised monoclonal antibodies :@0.084848:0.571965:0.480780:0.571965:0.480780:0.556209:0.084848:0.556209:0.013143:0.005715:0.012508:0.015086:0.011738:0.011699:0.018049:0.013143:0.011738:0.003848:0.007466:0.012508:0.013181:0.015086:0.018049:0.012604:0.011738:0.012604:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.015086:0.013143:0.011738:0.006523:0.003848:0.013123:0.012604:0.013181:0.003848:0.012508:0.007466:0.005330
that  block  the  interaction  between  PD-1 :@0.084848:0.587668:0.480782:0.587668:0.480782:0.571912:0.084848:0.571912:0.006523:0.011738:0.013143:0.006523:0.005330:0.003040:0.013123:0.003848:0.012604:0.012450:0.009660:0.005330:0.003048:0.006523:0.011738:0.012508:0.005330:0.003040:0.003848:0.011738:0.006523:0.012508:0.005792:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.003035:0.013123:0.012508:0.006523:0.015990:0.012508:0.012508:0.011738:0.005330:0.003040:0.011392:0.014316:0.006388:0.010660:0.005330
and its ligands, PD-L1 and PD-L2.  Binding :@0.084848:0.603371:0.480779:0.603347:0.480779:0.587591:0.084848:0.587615:0.013143:0.011738:0.013181:0.004916:0.003848:0.006523:0.007466:0.004926:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.007466:0.005330:0.004926:0.011392:0.014316:0.006388:0.008890:0.010660:0.004926:0.013143:0.011738:0.013181:0.004916:0.011392:0.014316:0.006388:0.008890:0.010660:0.005330:0.018636:0.004916:0.011045:0.003848:0.011738:0.013181:0.003848:0.011738:0.012950:0.124418
123:@0.383532:0.597728:0.402177:0.597728:0.402177:0.588542:0.383532:0.588542:0.006215:0.006215:0.006215
of the PD-1 ligands, PD-L1 and PD-L2, to :@0.084857:0.619050:0.480828:0.619050:0.480828:0.603294:0.084857:0.603294:0.012604:0.006042:0.008736:0.006523:0.011738:0.012508:0.008736:0.011392:0.014316:0.006388:0.010660:0.008736:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.007466:0.005330:0.008736:0.011392:0.014316:0.006388:0.008890:0.010660:0.008736:0.013143:0.011738:0.013181:0.008736:0.011392:0.014316:0.006388:0.008890:0.010660:0.005330:0.008736:0.006523:0.012604:0.005330
the PD-1 receptor found on T-cells, inhibits :@0.084857:0.634753:0.480791:0.634753:0.480791:0.618997:0.084857:0.618997:0.006523:0.011738:0.012508:0.005677:0.011392:0.014316:0.006388:0.010660:0.005696:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.005671:0.006042:0.012604:0.011699:0.011738:0.013181:0.005677:0.012604:0.011738:0.005677:0.008197:0.006388:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330:0.005686:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.007466:0.005330
T-cell proliferation and cytokine produc-:@0.084857:0.650456:0.475478:0.650456:0.475478:0.634700:0.084857:0.634700:0.008197:0.006388:0.012450:0.012508:0.003848:0.003848:0.009794:0.013123:0.005715:0.012604:0.003848:0.003848:0.006042:0.012508:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.009794:0.013143:0.011738:0.013181:0.009794:0.012450:0.010314:0.006523:0.012604:0.009660:0.003848:0.011738:0.012508:0.009794:0.013123:0.005715:0.012604:0.013181:0.011699:0.012450:0.006388
tion. Upregulation of PD-1 ligands occurs :@0.084857:0.666159:0.480799:0.666159:0.480799:0.650403:0.084857:0.650403:0.006523:0.003848:0.012604:0.011738:0.005330:0.008043:0.012604:0.013123:0.005711:0.012508:0.012950:0.011699:0.003848:0.013143:0.006523:0.003848:0.012604:0.011738:0.008043:0.012604:0.006042:0.008043:0.011392:0.014316:0.006388:0.010660:0.008043:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.007466:0.008057:0.012604:0.012450:0.012450:0.011699:0.005792:0.007466:0.005330
in some tumours,  and signalling through :@0.084857:0.681862:0.480820:0.681862:0.480820:0.666106:0.084857:0.666106:0.003848:0.011738:0.009775:0.007466:0.012604:0.018049:0.012508:0.009775:0.006523:0.011699:0.018049:0.012604:0.011690:0.005792:0.007466:0.005330:0.005330:0.004435:0.013143:0.011738:0.013181:0.009775:0.007466:0.003848:0.012950:0.011738:0.013143:0.003848:0.003848:0.003848:0.011738:0.012950:0.009775:0.006523:0.011738:0.005707:0.012604:0.011699:0.012950:0.011738:0.005330
this pathway can contribute to inhibition :@0.084857:0.697565:0.480799:0.697565:0.480799:0.681809:0.084857:0.681809:0.006523:0.011738:0.003848:0.007466:0.008197:0.013123:0.013143:0.006523:0.011738:0.015990:0.013143:0.010314:0.008197:0.012450:0.013143:0.011738:0.008188:0.012450:0.012604:0.011738:0.006523:0.005792:0.003848:0.013123:0.011699:0.006523:0.012508:0.008174:0.006523:0.012604:0.008182:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.003848:0.012604:0.011738:0.005330
of active T-cell immune surveillance of tu-:@0.084857:0.713268:0.475478:0.713268:0.475478:0.697512:0.084857:0.697512:0.012604:0.006042:0.006158:0.013143:0.012450:0.006523:0.003848:0.010660:0.012508:0.006158:0.008197:0.006388:0.012450:0.012508:0.003848:0.003848:0.006158:0.003848:0.018049:0.018049:0.011699:0.011738:0.012508:0.006158:0.007466:0.011699:0.005792:0.010660:0.012508:0.003848:0.003848:0.003848:0.013143:0.011738:0.012450:0.012508:0.006158:0.012604:0.006042:0.006158:0.006523:0.011699:0.006388
mours. Inhibition of PD-1 and ligand inter-:@0.084857:0.728971:0.475459:0.728971:0.475459:0.713215:0.084857:0.713215:0.018049:0.012604:0.011699:0.005792:0.007466:0.005330:0.006889:0.004349:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.003848:0.012604:0.011738:0.006889:0.012604:0.006042:0.006889:0.011392:0.014316:0.006388:0.010660:0.006889:0.013143:0.011738:0.013181:0.006889:0.003848:0.003848:0.012950:0.013143:0.011738:0.013181:0.006889:0.003848:0.011738:0.006523:0.012508:0.005792:0.006388
action  releases the  PD-1 pathway- :@0.084857:0.744674:0.480797:0.744674:0.480797:0.728918:0.084857:0.728918:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330:0.017478:0.005713:0.012508:0.003848:0.012508:0.013143:0.007466:0.012508:0.007466:0.022821:0.006523:0.011738:0.012508:0.005330:0.017476:0.011392:0.014316:0.006388:0.010660:0.022821:0.013123:0.013143:0.006523:0.011738:0.015990:0.013143:0.010314:0.006388:0.005330
mediated inhibition of  the  immune  re-:@0.084857:0.760377:0.475476:0.760377:0.475476:0.744621:0.084857:0.744621:0.018049:0.012508:0.013181:0.003848:0.013143:0.006523:0.012508:0.013181:0.012989:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.003848:0.012604:0.011738:0.012989:0.012604:0.006042:0.005330:0.007647:0.006523:0.011738:0.012508:0.005330:0.007643:0.003848:0.018049:0.018049:0.011699:0.011738:0.012508:0.005330:0.007647:0.005713:0.012508:0.006388
sponse, including the anti-tumour immune :@0.084857:0.776080:0.480793:0.776080:0.480793:0.760324:0.084857:0.760324:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330:0.005105:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.005103:0.006523:0.011738:0.012508:0.005099:0.013143:0.011738:0.006523:0.003848:0.006388:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005093:0.003848:0.018049:0.018049:0.011699:0.011738:0.012508:0.005330
response.  :@0.084857:0.791783:0.183973:0.791783:0.183973:0.776027:0.084857:0.776027:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330:0.005330:0.005330
Pembrolizumab:@0.084848:0.822564:0.246485:0.822564:0.246485:0.804543:0.084848:0.804543:0.011973:0.013683:0.020098:0.014111:0.006842:0.013683:0.005131:0.005131:0.009835:0.012828:0.020098:0.014111:0.014111
Pembrolizumab is indicated for the treat-:@0.084848:0.840878:0.475454:0.840878:0.475454:0.825122:0.084848:0.825122:0.011392:0.012508:0.018049:0.013123:0.005709:0.012604:0.003848:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.007524:0.003848:0.007466:0.007524:0.003848:0.011738:0.013181:0.003848:0.012450:0.013143:0.006523:0.012508:0.013181:0.007524:0.006042:0.012604:0.005792:0.007510:0.006523:0.011738:0.012508:0.007514:0.006523:0.005709:0.012508:0.013143:0.006523:0.006388
ment of:@0.084848:0.856581:0.157642:0.856581:0.157642:0.840825:0.084848:0.840825:0.018049:0.012508:0.011738:0.006523:0.005330:0.012604:0.006042
123:@0.157628:0.850958:0.176272:0.850958:0.176272:0.841772:0.157628:0.841772:0.006215:0.006215:0.006215
n :@0.084848:0.869744:0.098177:0.869744:0.098177:0.861304:0.084848:0.861304:0.009762:0.003566
 :@0.115149:0.869744:0.118715:0.869744:0.118715:0.861304:0.115149:0.861304:0.003566
Unresectable or metastatic :@0.115151:0.872863:0.373841:0.872863:0.373841:0.857107:0.115151:0.857107:0.012604:0.011738:0.005709:0.012508:0.007466:0.012508:0.012450:0.006523:0.013143:0.013123:0.003848:0.012508:0.005330:0.012604:0.005792:0.005330:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330
melanoma:@0.115151:0.888566:0.218233:0.888566:0.218233:0.872810:0.115151:0.872810:0.018049:0.012508:0.003848:0.013143:0.011738:0.012604:0.018049:0.013143
n :@0.084848:0.901728:0.098177:0.901728:0.098177:0.893288:0.084848:0.893288:0.009762:0.003566
 :@0.115149:0.901728:0.118715:0.901728:0.118715:0.893288:0.115149:0.893288:0.003566
Non-small-cell lung cancer :@0.115151:0.904847:0.369825:0.904847:0.369825:0.889091:0.115151:0.889091:0.014239:0.012604:0.011738:0.006388:0.007466:0.018049:0.013143:0.003848:0.003848:0.006388:0.012463:0.012508:0.003848:0.003848:0.005330:0.003848:0.011699:0.011738:0.012950:0.005330:0.012450:0.013143:0.011738:0.012450:0.012494:0.005792:0.005330
 :@0.084845:0.920550:0.090175:0.920550:0.090175:0.904794:0.084845:0.904794:0.005330
 –   as a single agent for the first-line treat- :@0.115148:0.920550:0.480796:0.920550:0.480796:0.904794:0.115148:0.904794:0.000000:0.009621:0.005330:0.015352:0.000000:0.012758:0.007081:0.003806:0.012758:0.003808:0.007081:0.003464:0.011353:0.012565:0.003464:0.012123:0.003806:0.012758:0.012565:0.012123:0.011353:0.006138:0.003808:0.005657:0.012219:0.005407:0.003806:0.006138:0.011353:0.012123:0.003806:0.004493:0.004493:0.005407:0.007081:0.006138:0.006004:0.003464:0.003464:0.011353:0.012123:0.003806:0.006138:0.005328:0.012123:0.012758:0.006138:0.006375:0.005330
ment of patients with metastatic :@0.145458:0.936253:0.440791:0.936253:0.440791:0.920497:0.145458:0.920497:0.017665:0.012123:0.011353:0.006138:0.004945:0.012219:0.005657:0.004945:0.012738:0.012758:0.006138:0.003464:0.012123:0.011353:0.006138:0.007081:0.004945:0.015606:0.003464:0.006138:0.011353:0.004945:0.017665:0.012123:0.006138:0.012758:0.007081:0.006138:0.012758:0.006138:0.003464:0.012450:0.005330
non-small-cell lung cancer with :@0.584551:0.079506:0.880153:0.079506:0.880153:0.063750:0.584551:0.063750:0.011738:0.012604:0.011738:0.006388:0.007466:0.018049:0.013143:0.003848:0.003848:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330:0.003848:0.011699:0.011738:0.012950:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330
tumours having high PD-L1 with no :@0.584551:0.095236:0.908804:0.095236:0.908804:0.079480:0.584551:0.079480:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.005330:0.011738:0.013143:0.010660:0.003848:0.011738:0.012950:0.005330:0.011738:0.003848:0.012950:0.011738:0.005330:0.011392:0.014316:0.006388:0.008890:0.010660:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.011738:0.012604:0.005330
EGFR or ALK genomic tumour :@0.584551:0.110965:0.862719:0.110965:0.862719:0.095209:0.584551:0.095209:0.010314:0.016779:0.009333:0.011680:0.005330:0.012604:0.005792:0.005330:0.014239:0.008890:0.011372:0.005330:0.012950:0.012508:0.011738:0.012604:0.018049:0.003848:0.012450:0.005330:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.005330
aberrations:@0.584551:0.126695:0.690230:0.126695:0.690230:0.110939:0.584551:0.110939:0.013143:0.013123:0.012508:0.005792:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466
 :@0.523937:0.142424:0.529267:0.142424:0.529267:0.126668:0.523937:0.126668:0.005330
 –   as a single agent for the treatment :@0.554240:0.142424:0.913230:0.142424:0.913230:0.126668:0.554240:0.126668:0.000000:0.009621:0.005330:0.015352:0.000000:0.013143:0.007466:0.005330:0.013143:0.005330:0.007466:0.003848:0.011738:0.012950:0.003848:0.012508:0.005330:0.013143:0.012950:0.012508:0.011738:0.006523:0.005330:0.006042:0.012604:0.005792:0.005330:0.006523:0.011738:0.012477:0.005330:0.006523:0.005707:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
of patients with metastatic non-:@0.584551:0.158154:0.880133:0.158154:0.880133:0.142398:0.584551:0.142398:0.012604:0.006042:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.011738:0.012604:0.011738:0.006388
small cell lung cancer whose :@0.584551:0.173883:0.858832:0.173883:0.858832:0.158127:0.584551:0.158127:0.007466:0.018049:0.013143:0.003848:0.003848:0.005330:0.012450:0.012508:0.003848:0.003848:0.005330:0.003848:0.011699:0.011738:0.012950:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.015990:0.011738:0.012604:0.007466:0.012508:0.005330
tumours express PD-L1 (TPS ≥1%) :@0.584551:0.189612:0.884197:0.189612:0.884197:0.173857:0.584551:0.173857:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.005330:0.012508:0.009236:0.013123:0.005700:0.012508:0.007466:0.007466:0.005330:0.011392:0.014316:0.006388:0.008890:0.010660:0.005330:0.007100:0.008197:0.011392:0.009583:0.005330:0.010564:0.010660:0.014913:0.007100:0.005330
with disease progression on or after :@0.584551:0.205342:0.917227:0.205342:0.917227:0.189586:0.584551:0.189586:0.015990:0.003848:0.006523:0.011738:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.013123:0.005719:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.012604:0.011738:0.005330:0.012604:0.005792:0.005330:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330
platinum-containing :@0.584551:0.221071:0.778822:0.221071:0.778822:0.205315:0.584551:0.205315:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330
chemotherapy:@0.584551:0.236801:0.725040:0.236801:0.725040:0.221045:0.584551:0.221045:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
 :@0.523937:0.252530:0.529267:0.252530:0.529267:0.236774:0.523937:0.236774:0.005330
 –   in combination with pemetrexed :@0.554240:0.252530:0.895077:0.252530:0.895077:0.236774:0.554240:0.236774:0.000000:0.009621:0.005330:0.015352:0.000000:0.003848:0.011738:0.005330:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.013123:0.012508:0.018049:0.012508:0.006523:0.005707:0.012508:0.009236:0.012508:0.013181:0.005330
and carboplatin, as first-line :@0.584551:0.268260:0.846690:0.268260:0.846690:0.252504:0.584551:0.252504:0.013143:0.011738:0.013181:0.005330:0.012450:0.013143:0.005792:0.013123:0.012604:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.005330:0.005330:0.013143:0.007466:0.005330:0.004686:0.004686:0.005792:0.007466:0.006523:0.006388:0.003848:0.003848:0.011738:0.012508:0.005330
treatment of patients with :@0.584551:0.283989:0.830713:0.283989:0.830713:0.268233:0.584551:0.268233:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.012604:0.006042:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330
metastatic non-squamous non-:@0.584551:0.299719:0.875573:0.299719:0.875573:0.283963:0.584551:0.283963:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.011738:0.012604:0.011738:0.006388:0.007466:0.013123:0.011699:0.013143:0.018049:0.012604:0.011699:0.007466:0.005330:0.011738:0.012604:0.011738:0.006388
small-cell lung cancer :@0.584551:0.315448:0.794254:0.315448:0.794254:0.299692:0.584551:0.299692:0.007466:0.018049:0.013143:0.003848:0.003848:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330:0.003848:0.011699:0.011738:0.012950:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330
n :@0.523939:0.328640:0.537267:0.328640:0.537267:0.320200:0.523939:0.320200:0.009762:0.003566
 :@0.554239:0.328640:0.557805:0.328640:0.557805:0.320200:0.554239:0.320200:0.003566
Head and neck squamous cell cancer:@0.554242:0.331760:0.913267:0.331760:0.913267:0.316004:0.554242:0.316004:0.013143:0.012508:0.013143:0.013181:0.005330:0.013143:0.011738:0.013181:0.005330:0.011738:0.012508:0.012450:0.009660:0.005330:0.007466:0.013123:0.011699:0.013143:0.018049:0.012604:0.011699:0.007466:0.005330:0.012450:0.012508:0.003848:0.003848:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792
 :@0.523935:0.347489:0.529265:0.347489:0.529265:0.331733:0.523935:0.331733:0.005330
 –   recurrent or metastatic head and :@0.554238:0.347489:0.903022:0.347489:0.903022:0.331733:0.554238:0.331733:0.000000:0.009621:0.005330:0.015352:0.000000:0.005713:0.012508:0.012450:0.011699:0.005792:0.005705:0.012508:0.011738:0.006523:0.005330:0.012604:0.005792:0.005330:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012434:0.005330:0.011738:0.012508:0.013143:0.013181:0.005330:0.013143:0.011738:0.013181:0.005330
neck squamous cell cancer with :@0.584549:0.363219:0.891638:0.363219:0.891638:0.347463:0.584549:0.347463:0.011738:0.012508:0.012450:0.009660:0.005330:0.007466:0.013123:0.011699:0.013143:0.018049:0.012604:0.011699:0.007466:0.005330:0.012450:0.012508:0.003848:0.003848:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330
disease progression on or after :@0.584549:0.379094:0.873798:0.379094:0.873798:0.363338:0.584549:0.363338:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.013123:0.005723:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.005330:0.012604:0.011738:0.005330:0.012604:0.005792:0.005330:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330
platinum-containing :@0.584549:0.394969:0.778820:0.394969:0.778820:0.379213:0.584549:0.379213:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330
chemotherapy:@0.584549:0.410844:0.725037:0.410844:0.725037:0.395088:0.584549:0.395088:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
n :@0.523939:0.424193:0.537267:0.424193:0.537267:0.415753:0.523939:0.415753:0.009762:0.003566
 :@0.554239:0.424193:0.557805:0.424193:0.557805:0.415753:0.554239:0.415753:0.003566
Hodgkin’s lymphoma:@0.554242:0.427313:0.751784:0.427313:0.751784:0.411557:0.554242:0.411557:0.013143:0.012604:0.013181:0.012950:0.009660:0.003848:0.011738:0.006754:0.007466:0.005330:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143
 :@0.523935:0.443188:0.529265:0.443188:0.529265:0.427432:0.523935:0.427432:0.005330
 –   adult and paediatric patients with :@0.554238:0.443188:0.908187:0.443188:0.908187:0.427432:0.554238:0.427432:0.000000:0.009621:0.005330:0.015352:0.000000:0.013143:0.013181:0.011699:0.003848:0.006523:0.005330:0.013143:0.011738:0.013181:0.005330:0.013123:0.013143:0.012508:0.013181:0.003848:0.013143:0.006523:0.005792:0.003848:0.012450:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330
refractory Hodgkin’s lymphoma, or :@0.584549:0.459063:0.912687:0.459063:0.912687:0.443307:0.584549:0.443307:0.005713:0.012508:0.006042:0.005792:0.013143:0.012450:0.006523:0.012604:0.005792:0.010314:0.005330:0.013143:0.012604:0.013181:0.012950:0.009660:0.003848:0.011738:0.006754:0.007466:0.005330:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.018049:0.013143:0.005330:0.005330:0.012604:0.005792:0.005330
who have relapsed after three or :@0.584549:0.474938:0.897773:0.474938:0.897773:0.459182:0.584549:0.459182:0.015990:0.011738:0.012604:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330:0.005703:0.012508:0.003848:0.013143:0.013123:0.007466:0.012508:0.013181:0.005330:0.013143:0.006042:0.006523:0.012508:0.005792:0.005330:0.006523:0.011738:0.005703:0.012508:0.012508:0.005330:0.012604:0.005792:0.005330
more prior lines of therapy:@0.584549:0.490813:0.827093:0.490813:0.827093:0.475057:0.584549:0.475057:0.018049:0.012604:0.005709:0.012508:0.005330:0.013123:0.005792:0.003848:0.012604:0.005792:0.005330:0.003848:0.003848:0.011738:0.012508:0.007466:0.005330:0.012604:0.006042:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
n :@0.523939:0.504164:0.537267:0.504164:0.537267:0.495724:0.523939:0.495724:0.009762:0.003566
 :@0.554239:0.504164:0.557805:0.504164:0.557805:0.495724:0.554239:0.495724:0.003566
Urothelial carcinoma:@0.554242:0.507283:0.749029:0.507283:0.749029:0.491527:0.554242:0.491527:0.012604:0.005713:0.012604:0.006523:0.011738:0.012508:0.003848:0.003848:0.013143:0.003848:0.005330:0.012450:0.013143:0.005655:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143
 :@0.523935:0.523158:0.529265:0.523158:0.529265:0.507402:0.523935:0.507402:0.005330
 –   locally advanced or metastatic :@0.554238:0.523158:0.884488:0.523158:0.884488:0.507402:0.554238:0.507402:0.000000:0.009621:0.005330:0.015352:0.000000:0.003848:0.012604:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.005330:0.012604:0.005792:0.005330:0.018049:0.012496:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330
urothelial carcinoma in patients :@0.584549:0.539033:0.884880:0.539033:0.884880:0.523277:0.584549:0.523277:0.011699:0.005711:0.012604:0.006523:0.011738:0.012508:0.003848:0.003848:0.013143:0.003848:0.005330:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.003848:0.011738:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
who are not eligible for cisplatin-:@0.584549:0.554908:0.887049:0.554908:0.887049:0.539152:0.584549:0.539152:0.015990:0.011738:0.012604:0.005330:0.013143:0.005705:0.012508:0.005330:0.011738:0.012604:0.006523:0.005330:0.012508:0.003848:0.003848:0.012950:0.003848:0.013123:0.003848:0.012508:0.005330:0.006042:0.012604:0.005792:0.005330:0.012450:0.003848:0.007466:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.006388
containing chemotherapy:@0.584549:0.570783:0.830948:0.570783:0.830948:0.555027:0.584549:0.555027:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
 :@0.523935:0.586658:0.529265:0.586658:0.529265:0.570902:0.523935:0.570902:0.005330
 –   locally advanced or metastatic :@0.554238:0.586658:0.884488:0.586658:0.884488:0.570902:0.554238:0.570902:0.000000:0.009621:0.005330:0.015352:0.000000:0.003848:0.012604:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.005330:0.012604:0.005792:0.005330:0.018049:0.012496:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330
urothelial carcinoma in patients :@0.584549:0.602533:0.884880:0.602533:0.884880:0.586777:0.584549:0.586777:0.011699:0.005711:0.012604:0.006523:0.011738:0.012508:0.003848:0.003848:0.013143:0.003848:0.005330:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.005330:0.003848:0.011738:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
whose disease has progressed :@0.584549:0.618408:0.871868:0.618408:0.871868:0.602652:0.584549:0.602652:0.015990:0.011738:0.012604:0.007466:0.012508:0.005330:0.013181:0.003848:0.007466:0.012508:0.013143:0.007466:0.012508:0.005330:0.011738:0.013143:0.007466:0.005330:0.013123:0.005715:0.012604:0.012950:0.005707:0.012508:0.007466:0.007466:0.012508:0.013181:0.005330
during or following platinum-:@0.584549:0.634283:0.849978:0.634283:0.849978:0.618527:0.584549:0.618527:0.013181:0.011699:0.005792:0.003848:0.011738:0.012950:0.005330:0.012604:0.005792:0.005330:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388
containing chemotherapy or within :@0.584549:0.650158:0.919020:0.650158:0.919020:0.634402:0.584549:0.634402:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.012604:0.005792:0.005330:0.015990:0.003848:0.006523:0.011738:0.003848:0.011738:0.005330
12 months of neoadjuvant or :@0.584549:0.666033:0.858522:0.666033:0.858522:0.650277:0.584549:0.650277:0.010660:0.010660:0.005330:0.018049:0.012604:0.011738:0.006523:0.011738:0.007466:0.005330:0.012604:0.006042:0.005330:0.011738:0.012508:0.012604:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.012604:0.005792:0.005330
adjuvant treatment with platinum-:@0.584549:0.681908:0.904219:0.681908:0.904219:0.666152:0.584549:0.666152:0.013143:0.013181:0.003906:0.011699:0.010660:0.013143:0.011738:0.006523:0.005330:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.006388
containing chemotherapy:@0.584549:0.697783:0.830948:0.697783:0.830948:0.682027:0.584549:0.682027:0.012450:0.012604:0.011738:0.006523:0.013143:0.003848:0.011738:0.003848:0.011738:0.012950:0.005330:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
n :@0.523939:0.711147:0.537267:0.711147:0.537267:0.702707:0.523939:0.702707:0.009762:0.003566
 :@0.554239:0.711147:0.557805:0.711147:0.557805:0.702707:0.554239:0.702707:0.003566
Microsatellite instability-high cancer:@0.554242:0.714266:0.886400:0.714266:0.886400:0.698510:0.554242:0.698510:0.017684:0.003848:0.012450:0.005715:0.012604:0.007466:0.013143:0.006523:0.012508:0.003848:0.003848:0.003848:0.006523:0.012508:0.005330:0.003848:0.011738:0.007466:0.006523:0.013143:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.006388:0.011738:0.003848:0.012966:0.011738:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792
 :@0.523935:0.730141:0.529265:0.730141:0.529265:0.714385:0.523935:0.714385:0.005330
 –   adult and paediatric patients with :@0.554238:0.730141:0.909572:0.730141:0.909572:0.714385:0.554238:0.714385:0.000000:0.009621:0.005330:0.016749:0.000000:0.013143:0.013181:0.011699:0.003848:0.006523:0.005330:0.013143:0.011738:0.013181:0.005330:0.013123:0.013143:0.012508:0.013181:0.003848:0.013143:0.006523:0.005792:0.003848:0.012450:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.015990:0.003848:0.006523:0.011738:0.005330
unresectable or metastatic, :@0.585934:0.746016:0.849049:0.746016:0.849049:0.730260:0.585934:0.730260:0.011699:0.011738:0.005709:0.012508:0.007466:0.012508:0.012450:0.006523:0.013143:0.013123:0.003848:0.012508:0.005330:0.012604:0.005792:0.005330:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.005330:0.005330
microsatellite instability-high :@0.585934:0.761891:0.850363:0.761891:0.850363:0.746135:0.585934:0.746135:0.018049:0.003848:0.012450:0.005715:0.012604:0.007466:0.013143:0.006523:0.012508:0.003848:0.003848:0.003848:0.006523:0.012508:0.005330:0.003848:0.011738:0.007466:0.006523:0.013143:0.013123:0.003848:0.003848:0.003848:0.006523:0.010314:0.006388:0.011738:0.003848:0.012950:0.011738:0.005330
(MSI-H) or mismatch-repair- :@0.585934:0.777766:0.843836:0.777766:0.843836:0.762010:0.585934:0.762010:0.007100:0.017684:0.009583:0.004349:0.006388:0.013143:0.007100:0.005330:0.012604:0.005792:0.005330:0.018049:0.003848:0.007466:0.018049:0.013143:0.006523:0.012450:0.011738:0.006388:0.005711:0.012508:0.013123:0.013143:0.003848:0.005792:0.006388:0.005330
deficient :@0.585934:0.793641:0.673391:0.793641:0.673391:0.777885:0.585934:0.777885:0.013181:0.012508:0.004686:0.004686:0.012450:0.003848:0.012508:0.011738:0.006523:0.005330
 :@0.523935:0.809516:0.529265:0.809516:0.529265:0.793760:0.523935:0.793760:0.005330
   :@0.554238:0.809516:0.559568:0.809516:0.559568:0.793760:0.554238:0.793760:0.005330:-0.005330:0.005330
•   solid tumours that have :@0.585934:0.809516:0.833661:0.809516:0.833661:0.793760:0.585934:0.793760:0.011661:0.005330:0.008665:0.000000:0.007466:0.012604:0.003848:0.003848:0.013181:0.005330:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.005330:0.006523:0.011738:0.013143:0.006523:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330
progressed following prior :@0.611584:0.825391:0.855434:0.825391:0.855434:0.809635:0.611584:0.809635:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.012508:0.013181:0.005330:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.013123:0.005792:0.003848:0.012604:0.005792:0.005330
treatment and which have no :@0.611584:0.841266:0.897676:0.841266:0.897676:0.825510:0.611584:0.825510:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.013143:0.011738:0.013181:0.005330:0.015990:0.011738:0.003848:0.012450:0.011738:0.005330:0.011738:0.013143:0.010660:0.012508:0.005330:0.011738:0.012604:0.005330
satisfactory alternative :@0.611584:0.857141:0.828194:0.857141:0.828194:0.841385:0.611584:0.841385:0.007466:0.013143:0.006523:0.003848:0.007466:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.010314:0.005330:0.013143:0.003848:0.006523:0.012508:0.006194:0.011738:0.013143:0.006523:0.003848:0.010660:0.012508:0.005330
treatment options, or :@0.611584:0.873016:0.812433:0.873016:0.812433:0.857260:0.611584:0.857260:0.006523:0.005711:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.012604:0.013123:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330:0.005330:0.012604:0.005792:0.005330
 :@0.523916:0.888891:0.529246:0.888891:0.529246:0.873135:0.523916:0.873135:0.005330
   :@0.554219:0.888891:0.559549:0.888891:0.559549:0.873135:0.554219:0.873135:0.005330:-0.005330:0.005330
•   colorectal cancer that has :@0.585915:0.888891:0.866923:0.888891:0.866923:0.873135:0.585915:0.873135:0.011661:0.005330:0.008665:0.000000:0.012450:0.012604:0.003848:0.012604:0.005707:0.012508:0.012450:0.006523:0.013143:0.003848:0.005330:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005330:0.006523:0.011738:0.013143:0.006523:0.005330:0.011738:0.013143:0.007466:0.005330
progressed following treatment :@0.611565:0.904766:0.907475:0.904766:0.907475:0.889010:0.611565:0.889010:0.013123:0.005713:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.012508:0.013181:0.005330:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.006523:0.005707:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330
with a fluoropyrimidine, :@0.611565:0.920496:0.832318:0.920496:0.832318:0.904740:0.611565:0.904740:0.015990:0.003848:0.006523:0.011738:0.005330:0.013143:0.005330:0.004666:0.004666:0.011699:0.012604:0.005700:0.012604:0.013123:0.010314:0.005792:0.003848:0.018049:0.003848:0.013181:0.003848:0.011738:0.012508:0.005330:0.005330
oxaliplatin, and irinotecan :@0.611565:0.936225:0.860042:0.936225:0.860042:0.920469:0.611565:0.920469:0.012604:0.009236:0.013143:0.003848:0.003848:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.005330:0.005330:0.013143:0.011738:0.013181:0.005330:0.003848:0.005792:0.003848:0.011738:0.012604:0.006523:0.012508:0.012450:0.013143:0.011738:0.005330
DRUG-CLASS OVERVIEW:@0.084848:0.038601:0.357590:0.038601:0.357590:0.019343:0.084848:0.019343:0.017498:0.014276:0.015405:0.020508:0.007808:0.019121:0.010866:0.017404:0.011712:0.011712:0.006515:0.020438:0.016510:0.012606:0.013356:0.016510:0.005315:0.012606:0.022578